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Abstract
Breast cancer patients have an anomalously high rate of relapse many years–up to 25 years–after apparently curative surgery
removed the primary tumour. Disease progression during the intervening years between resection and relapse is poorly
understood.There isevidence that thediseasepersists asdangerous, tinymetastases that remainatagrowthrestricted, clinically
undetectable size until a transforming event restarts growth. This is the starting point for our study, where patients who have
metastases that are all tiny and growth-restricted are said to have cancer dormancy. Can long-term follow-up relapse data from
breast cancer patients be used to extract knowledge about the progression of the undetected disease? Here, we evaluate
whether this is the case by introducing and analysing four simple mathematical models of cancer dormancy. These models
extend the common assumption that a random transforming event, such as a mutation, can restart growth of a tiny, growth-
restrictedmetastasis; thereafter, cancer dormancyprogresses todetectablemetastasis.We find that physiopathological details,
such as thenumberof randomtransformingevents thatmetastasesmust undergo toescape fromgrowth restriction, cannotbe
extracted fromrelapsedata.This result isunsurprising.However, thesameanalysis suggestedanaturalquestion thatdoeshavea
surprising answer: why are interesting trends in long-term relapse data not more commonly observed? Further, our models
indicate that (a) therapies which induce growth restriction among metastases but do not prevent increases in metastases’
tumourigenicitymay introduce a timepost-surgerywhenmorepatients are prone to relapse; and (b), if a number of facts about
diseaseprogressionarefirstestablished,howrelapsedatamightbeusedtoestimateclinically relevantvariables, suchasthe likely
numbers of undetected growth-restrictedmetastases. Thiswork is a necessary, early step in building aquantitativemechanistic
understanding of cancer dormancy.
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Introduction
In breast cancer it is relatively common when compared with
other cancers for patients to relapse from metastases appearing at
distant sites after exceptionally long periods of remission, up to 25
years [1]. The dynamics of disease progression during the
intervening years between resection and relapse is largely
unknown [2]. Evidence that the periods of remission are
inexplicable by continual growth of metastases [3–7] implies that
there is some period during which all metastases are not growing–
they are growth-restricted at sizes and locations that cannot be
detected by non-invasive clinical methods. In this study, such
patients are said to have breast cancer dormancy.
Growth restriction of tiny metastases could be due to their
inability to recruit extra blood vessels required for further growth
(cells are pre-angiogenic) [8–14], or to immune surveillance
[15,16], or to cell-cycle arrest of disseminated cells [17], perhaps
because the new microenvironment lacks the cues to reverse the
epithelial-mesenchymal transition [18,19]. Disseminated cancer
cells are thought to have been found in the blood of breast cancer
patients who show no other signs of relapse up to 22 years post-
resection [20], and these cells are thought to have a short life-span
[20], which would indicate that long-term dormancy in breast
cancer is maintained by micrometastases that contain proliferating
cells rather than by solitary quiescent cells.
Given the experimental constraints that prohibit the study of
dormancy in vivo, a few recent efforts have attempted to infer the
physiopathologicalmechanismsunderlyingdormancy fromtrends in
relapse statistics collected from large, long-term follow-up cohorts of
patients with previously resected cancers [21,22]. The approach is
analogous to that initiated by Armitage and Doll in the 1960 s, who
attempted to infer the number of rate-limiting events that occurred
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during carcinogenesis from age-onset data [23]. FollowingArmitage
and Doll, more recent work proved that definitive estimates of this
numberare confoundedbyclonal expansions that occuraspart of the
carcinogenicprocess (see [24]andreferences therein) andas such, the
physiopathological information extractable from the age-incidence
data is limited. It seems pertinent to ask what information about the
progression of long-term metastatic disease can be confidently
inferred from relapse statistics.
Here, we address this question in the context of breast cancer
dormancy by introducing and analysing four simple probabilistic
models, each motivated by the clinical literature. These models
have in common one key assumption, that all patients who relapse
beyond a specified minimum time t years post-resection have
metastases that each underwent at least one period of growth
restriction as a micrometastasis until a random growth event, such
as a (epi)mutation among the proliferating cells, caused escape
from growth restriction. Otherwise the different models represent
different combinations of the following physiopathological events:
(1) Micrometastases may disappear–the spontaneous disappear-
ance of small cancers and metastases is known to happen (e.g. [25–
27]); it is often attributed to immune attack or random fluctuations
in the balance of cell proliferation and death. (2) Micrometastases
may disseminate cells that seed secondary micrometastases at
distant sites–this is plausible because the cell-initiators of micro-
metastases are likely to have high metastatic potential, and breast
cancer dormancy patients commonly have circulating tumour cells
in their blood [20]. (3) Micrometastases undergo two rate-limiting,
random growth events, rather than just one–there is evidence for
two significant periods of growth restriction, as solitary cells [17]
and as pre-angiogenic micrometastases [8], that may follow in
succession in breast cancer dormancy [28]. (4) The rate of escape
from growth restriction may change over time–for example, if over
generations selection operates on the cells of the micrometastases
to increase the cell proliferation rate.
Each model makes simplifying assumptions: the physiopatho-
logical events (1)–(4) are each represented by parameters that
coarse-grain many, largely unknown, distinct cellular events; each
model ignores fluctuations in cell number and intra-heterogeneity
within micrometastases; each model ignores the inter-heterogeni-
ety between micrometastases and their respective locations; after a
random growth event, micrometastases grow to a clinically
detectable size over a fixed growth time t that is common to all
micrometastases; micrometastases are assumed not to influence
one another’s progression. Lastly, the effect of treatments on
disease progression is not explicitly modelled, although it may be
possible to surmise how treatments will affect relapse rates from
their likely effect on the parameters representing (1) – (4) (see, for
example, the third section of the results). We return briefly to these
assumptions in the discussion.
Despite the simplifications, the models can account for the
different trends in relapse data. Their simplicity renders them
analytically tractable, and this permitted a full characterisation of
how the disease’s hidden dynamics translates into trends in relapse
data, and so led to a few surprising conclusions that are
summarised in the discussion. The characterisation would have
been considerably more difficult and perhaps impossible to
achieve with more complex models.
Materials and Methods
Models
Patients post-resection can be in one of four states: all metastases
in growth restriction as micrometastases (dormancy); one or more
growing metastases (growth); detectable metastases (relapse); or no
residual cancer (clearance). The following models, illustrated in
Figure 1, describe four different scenarios for how a patient, who
at the time of resection has no detectable or growing cancers,
progresses between these states. Their specifications as continuous-
time Markov processes are in File S1. In each model, the total
number of micrometastases in a patient at time t post-resection is
n(t) (or ni(t), i~A,B, . . . if there are different types A,B . . . of
micrometastases). Notation is summarised in Table 1.
Zeroth Model : micrometastases escape from growth
restriction in one rate-limiting step. Upon resection the
patient has n(0)~N growth-restricted micrometastases. If Nw0,
the patient has dormancy; otherwise N~0 and the patient is
cleared of cancer. Each micrometastasis undergoes a random
growth event at steady average rate k per year, so the total rate of
escape from growth restriction at time t is k|n(t); in the Zeroth
Model k|n(t)~k|N , i.e. the risk to the patient remains
constant until a growth event. If the growth event is a mutation,
k coarse-grains the likelihood of the mutation per cell prolifera-
tion, the cell proliferation rate, and the number of proliferating
cells in a micrometastasis. Following this event, it is only a matter
of time, denoted by a specified growth time t, until the
micrometastasis grows to a clinically detectable size and the
patient relapses. The Zeroth Model has 2 parameters N,k.
Models 1 to 3 generalize the Zeroth Model in three different
ways.
Model 1 : the cells of micrometastases can seed
secondary micrometastases and micrometastases can
disappear. In Model 1 [22], the N micrometastases present
upon resection are subject not only to growth events occurring at
rate k per year, in addition they may disappear at rate m per year,
or their disseminated cells may seed new, growth-restricted,
secondary micrometastases at rate l per year. In this way the
number of micrometastases n(t) may change with time t: the risk
to the patient increases as new micrometastases are seeded or
decreases as micrometastases disappear. The parameter l coarse-
grains many cellular events, including cell dissemination and
colonization in a new environment. The metastatic potential of
breast cancer cells depends on the micro-environment from which
they originate [29]; we assume that only some micro-environments
permit seeding of secondary micrometastases. Another parameter
pM accounts for the frequency with which micrometastases are
independently seeded in micro-environments that permit second-
ary metastasis; the number of micrometastases in such environ-
ments is denoted nM (t).
Model 1 has 5 parameters N,k,m,l,pM .
Model 2 : micrometastases must undergo two rate-
limiting steps to escape from growth restriction. In Model
2, micrometastases are of two types. Type one, of number
nV (0)~NV upon resection, must undergo one random growth
event to grow to a detectable size; the growth event occurs at
steady rate kV per micrometastasis per year. Type two, of number
nS(0)~NS upon resection, must undergo two random growth
events to grow to a detectable size. The first growth event occurs at
rate kS per micrometastasis per year, the second growth event
occurs at rate kV per micrometastasis per year; when such
micrometastases undergo a first growth event, the patient still has
dormancy, but the risk to the patient increases. Model 2 is
motivated by the following scenario [21]: growth-restricted
quiescent cell clumps (micrometastases in state S) suddenly
proliferate to grow to pre-angiogenic micrometastases (microme-
tastases in state V ); micrometastases seeded by the primary tumour
can be in either state S or state V . Micrometastases cannot
disappear, nor is there dynamic seeding of secondary microme-
tastases.
Disease Progression in Breast Cancer Dormancy
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Model 2 has 4 parameters NS,NV ,kS,kV .
Model 3 : micrometastases escape from growth
restriction at a rate that changes with time. In Model 3,
the rate of escape from growth restriction is no longer steady: it
varies with time in each micrometastasis as k(t) per year because,
for example, there is a gradual selection among the cells of each
micrometastasis which gradually increases the cell proliferation
rate and so the growth event rate. For data fitting, it is simplest to
assume that k(t) is linear k(t)~k0zk’0t. Here, all micrometas-
tases, of number n(0)~N upon resection, are of the same type,
and again micrometastases cannot disappear nor is there dynamic
seeding of secondary micrometastases.
Model 3 has 3 parameters N,k0,k’0.
Analysis
Relapse data are systematically summarized by Kaplan-Meier
recurrence-free interval curves (from hereon referred to as RFI
curves) which show the post-resection time evolution of the
fraction of patients who do not have recurrent breast cancer as it is
defined below in the section`Relapse data’. Throughout, ft½tzt
denotes a RFI curve at tzt years post-resection normalized at
time t (the normalization time is indicated by the subscript,
ft½tzt~f0½tzt=f0½t). Using RFI curves only after the micro-
metastases’ growth time t excludes from our analyses patients who
already had growing or detectable metastases upon resection. The
hazard rate h½tzt is the rate of patient relapse among those who
have survived recurrence-free until that time, and so is related to
the RFI curve by h½tzt~{f ’t½tzt=ft½tzt.
Expressions that relate the models’ variables to RFI
curves and hazard rates. For each model, the statistics
Figure 1. Models. The four models describe four different scenarios for how a patient, who at the time of resection has no detectable or growing
cancers, progresses between the states of dormancy, clearance, growth, and relapse.
doi:10.1371/journal.pone.0062320.g001
Table 1. Abbreviations and notation.
RFI (breast cancer) recurrence-free interval
EBCTCG Early Breast Cancer Trials Collaborative Group
ER +/2 estrogen receptor positive/negative
ft[t+t] RFI curve at time t+t post-resection, normalized at time t
h[t+t] Hazard rate at time t+t post-resection
Et[?], Vart[?] Average, variance at time t post-resection among patients without growing or detectable metastases
n(ni, i =A, B,…) Number of micrometastases (of type i=A, B,…)
doi:10.1371/journal.pone.0062320.t001
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ft½tzt and h½tzt are expressible in terms of the model’s
variables and parameters. Recall that n denotes the number of
micrometastases. The expressions below are derived in File S1.
Zeroth Model : h½tzt~Et½kn, h’½tzt~{Vart½kn ð1Þ
Model 1 : h½tzt~Et½kn, h’½tzt~Et½k(lnM{mn)
{Vart½kn
ð2Þ
Model 2 : h½tzt~Et½kVnV ,h’½tzt~Et½kS kV nS
{Vart½kV nV 
ð3Þ
Model 3 : h½tzt~Et½k(t)n, h’½tzt~Et½k’(t)n
{Vart½k(t)n:
ð4Þ
The expectation Et½: and the variance Vart½: are over patients
without growing or detectable metastases at time t post-resection. (Note that
(1) – (4) relate hazard rates at time tzt post-resection to n at time t
post-resection.) Under the assumption that upon resection
parameters are independent, we have.
ZerothModel :
f ’’t ½t~ (k2zs2k)(N2zs2N )
h’½t~ {k2s2N{s2k(N2zs2N )
"
ð5Þ
Model 1 :
f ’’t ½t~ {k(pM l{m)Nz(k2zs2k)(N2zs2N )
h’½t~ k(p
M
l{m{k
s2
N
N
)N{s2k(N
2zs2N )
2
4 ð6Þ
Model 2 :
f ’’t ½t~ {kS kV NSz(k2Vzs2kV )(N
2
Vzs
2
NV
)
h’½t~ kSkV NS{k2V s2NV{s
2
kV
(N2Vzs
2
NV
)
"
ð7Þ
Model 3 :
f ’’t ½t~ {k’0Nz(k20zs2k0 )(N
2zs2N )
h’½t~ k’0N{k20s2N{s2k0 (N
2zs2N )
"
ð8Þ
where here fN,k,m,l,pMg, fNS,NV ,kS,kVg, and fN,k0,k’0g each
represent the corresponding population averages among patients,
and fs2N ,s2kg, fs2NV ,s
2
kV
g, and fs2N ,s2k0g each represent the
population variance of the parameter indicated by the subscript
(compare (1) – (4)). In data fitting and the presentation of results, it
is assumed that s2k~s
2
kV
~s2k0
~0 (all patients have the same k or
kV ), and that the number of micrometastases upon resection is
Poisson-distributed with mean N (or with means Ni, i~A,B, . . ., if
micrometastases have different types). The latter assumption is
equivalent to the very reasonable assumption that the microme-
tastases extant upon resection were all seeded by a primary tumour
which seeds metastases as a time-varying Poisson process. The
former assumption is evaluated in the results and in the discussion.
Relapse Data
Models are fitted to relapse data from the following long-term
follow-up studies of relapse among breast cancer patients who did
not receive adjuvant therapy : 1) two data sets from the Early
Breast Cancer Trialists Collaborative Group (EBCTCG), a 15-
year follow-up from 6399 female patients [30]; 2) two data sets
from Chia et al., a 10-year follow-up from 1,187 lymph-node
negative, lymphovascular negative female patients [31]. The two
EBCTCG data sets are women aged less than 50 years at diagnosis
and women aged 50–69 years at diagnosis. The two Chia et al.
data sets are distinguished by the estrogen receptor positive (ER+)
or negative (ER2) status of the primary tumour. This indicates a
patient’s likely response to endocrine therapies such as tamoxifen.
The software GraphClick [32] was used to extract RFI curves
from these studies.
The models of dormancy are suitably applied to breast cancer
relapse data that specifies patients’ recurrence-free intervals (RFIs)
[33]. This term was introduced in 2007 [33] to describe patient
relapse data where relapses or `recurrences’ or `end points’ are
defined to be any one of the following: local/regional invasive
recurrence; distant recurrence; invasive ipsilateral breast tumour
recurrence (these are presumed to be a recurrence); death from
breast cancer before a recorded relapse. Among studies carried out
prior to 2007 (and possibly since 2007), there are often
discrepancies in the definitions of breast cancer relapses [33]. In
the Chia et al. study, relapses were defined as either the first local
(breast or chest wall), regional (ipsilateral axillary, infraclavicular,
internal mammary or supraclavicular), or distant recurrence, or
death from breast cancer before a recorded relapse, while new
contralateral breast cancers were not included. In the EBCTCG
study, relapses were defined as the first reappearance of breast
cancer at any site, and so new contralateral cancers were included
along with the other ‘end points’ specified in [33]. The EBCTCG
and Chia et al. data were used because they are from large patient
cohorts which ensured that RFI curves were sufficiently smooth for
trends in the data to be apparent. The analysis presented in this
article leads to methods for establishing results that are quick and
easy to repeat on new large cohort data sets as they become
available. In the future, as it becomes possible, the models are most
suitably applied to large cohort data sets for which it has been
unambiguously established that relapses are due to the original
tumours. However, applying this stricter definition to relapse data
should not alter the results or conclusions in this article.
Model Fitting
For each model and relapse data set, fitting was by a Monte
Carlo method: fitted parameter values are the points in parameter
space from a random sample of 106 which gave the minimum total
squared deviation between model and data. Points were sampled
from a uniform distribution over the following volumes: for the
Zeroth Model, fE½N,kg*½0,10|½0,0:3; for Model 1,
fN,k,m,l,pMg*½0,10|½0,0:1|½0,3|½0,3|½0,1; for Model
2, fNS,NV ,kS ,kVg*½0,10|½0,10|½0,3|½0,0:3; for Model 3,
fN,k0,k’0g*½0,10|½0,0:3|½0,0:2. These volumes are sensible,
and our conclusions are independent of them. For each randomly
sampled point, the total squared deviation between the model’s
RFI curve (explicit functional forms of RFI curves are derived for
each model in File S1) and the data set was recorded. The growth
time t was specified as 3 years for EBCTCG data and 1.5 years for
Chia et al. data; these choices for t are sensible, see File S1), and
for these specific data sets they demonstrate our results optimally,
while our conclusions are independent of the choice.
Disease Progression in Breast Cancer Dormancy
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Results
Physiopathological Details about Disease Progression
cannot be Inferred by Fitting Models to Relapse Data
Figure 2 shows the Zeroth Model and Models 1–3 fitted to data
from EBCTCG (Panel A) and Chia et al. (Panel B). The graphs in
each panel show that each model gives a good fit to both data sets.
Hazard rates are inset in each graph; parameters and total squared
deviations are in Table 2. There is one notable difference among
the fitted models: for the ER+ Chia et al. data set, the hazard rate
has a maximum; Models 1–3 can reproduce this maximum but the
Zeroth Model cannot, as is explained in the next section.
Consequently, Models 1–3 give a better fit than the Zeroth Model
(they consistently have a smaller total squared deviation; other
discrepancies in the total squared deviations are due to the Monte
Carlo fitting method).
Maxima in Hazard Rates are Expected if the
Tumourigenicity of Micrometastases Increases with Time
According to Models 1–3, the hazard rate is increasing at time t
years post-resection whenever the following inequalities are
satisfied.
Model 1 :
p
M
l{mwk (the number of micrometastases increases)
Model 2 :
kSNSwkV NV (more micrometastases require just
1 growth event)
Model 3 :
k00
k0
wk0 (faster escape in each micrometastasis)
(h’½tw0 in equations (6) – (8)). The Zeroth Model cannot account
for an increase in the hazard rate. The different inequalities get
different mechanistic interpretations for increasing hazard rates,
but these interpretations have a common base: the risk of escape
from growth restriction increases (by the mechanisms in paren-
theses) before any micrometastasis escapes from growth restric-
tion–we say that the tumourigenicity of micrometastases increases.
Some hazard rates from long-term follow-up breast cancer data
are still increasing at times exceeding 5 years post-resection [34–
36], but a literature survey indicates that presently long-term
hazard rates are mostly decreasing or flat (see e.g. Figure 2, and
File S1 for a description of how Models 1–3 can account for the
extant hazard rates with multiple maxima). Given that cancer cells
of micrometastases are thought to be actively dividing, increases in
micrometastases’ tumourigenicity by some mechanism seems
likely. The question then becomes, why are hazard rates from
long-term follow-up relapse data sets not more commonly
increasing? Expressions (2) – (4) indicate that such trends are
obscured by variances among disease course.
Dormancy-inducing Therapies may Introduce a Period
During which More Patients are Prone to Relapse
Models 1–3 produce RFI curves with a maximum in the relapse
rate–i.e. a period when more patients are prone to relapse–when
the following inequalities are satisfied
Model 1 : p
M
l{mwk(1zN)
Model 2 : kS
NS
NV
wkV (1zNV )
Model 3 :
k00
k0
wk0 (1zN)
(f ’’t ½tv0 in equations (6) – (8); the relapse rate is{f ’t½tzt), see
Figure 3. The Zeroth Model cannot produce RFI curves that have
a maximum in the relapse rate. These inequalities are more likely
to be satisfied as k or N (Model 1), kV or NV (Model 2), k0 or N
(Model 3) decrease. Therefore, each model indicates that therapies
administered upon resection which either (a) induce a period of
growth restriction of metastases or (b) eliminate micrometastases
that require just one random growth event to escape from growth
restriction, but which do not prevent cancer cell proliferation and
so prevent increases in micrometastases’ tumourgenicity, can
introduce a period during which there is an increased rate of
patient relapse. This does not imply that such therapies will
increase the total number of relapsing patients.
Estimating Long-term Averages and Standard Deviations
in the Number of Patients’ Micrometastases
It may often be valid to make the assumption that from 10 years
post-resection the tumourigenicity of micrometastases among
patients who have no growing or detectable metastases is no
longer changing: e.g. in Model 1, all patients with micrometastases
that can seed secondary micrometastases have already relapsed; in
Model 2, all micrometastases that must undergo two growth events
to escape from growth restriction have already undergone one
growth event; in Model 3, micrometastases’ cell proliferation rate
is no longer increasing. Then in equations (1) – (4) the first term on
the right is zero; Models 1–3 all collapse to the Zeroth Model, and
for a given k we have
Models 0{{3 : Et½n&h½tzt=k, Vart½n&{h0½tzt=k2
.where in Model 2 k represents kV . Clearly this approximation
can apply only from a time beyond which the hazard rate is non-
increasing.
The hazard rates from the EBCTCG and Chia et al. data sets
(insets, Figure 2) are extrapolated up to 20 years post-resection in
order to plot the average Et½n and the standard deviation
SDt½n~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Vart½n
p
for different values of k, see Figure 4. The plots
show that from 10 years post-resection, for both data sets, the
averages have a value of one or less and the standard deviations
have a value of three or less whenever k§0:02 (k§0:02 is
equivalent to micrometastases escaping from growth restriction
within 50 years). This is a quick, approximate method for
corroborating our former study [22] which found that long-term
breast cancer dormancy can be maintained by small numbers of
micrometastases, provided that on average micrometastases escape
from growth restriction within a number of years that is less than a
human lifetime. Note that if, for a particular data set, a stricter
definition of breast cancer recurrence is adopted (as discussed in
the methods section` Relapse data’), then the corresponding hazard
Disease Progression in Breast Cancer Dormancy
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rate is expected to be reduced. We see from the approximation
above that this would strengthen our former conclusion that long-
term breast cancer dormancy can be maintained by small numbers
of micrometastases: the conditional clause becomes, micrometas-
tases escape from growth restriction within a number of years that
can exceed a human lifetime.
Discussion
Different simple mechanistic models of metastatic progression in
cancer dormancy can all account equally well for the different
trends in long-term follow-up relapse data. We recommend,
therefore, that trends in relapse data be not used as evidence of the
physiopathological mechanisms underlying metastatic progression.
If breast cancer dormancy is due to growth-restricted micro-
metastases that contain proliferating cells, then one might expect
the tumourigenicity of the micrometastases, and so the risk to the
patient, to increase with time before the micrometastasis escapes
from growth restriction, perhaps owing to an evolutionary
dynamics among cells of the micrometastasis. If this is the case,
then it is intuitive that the hazard rate should increase to a
maximum before decreasing and our models corroborate this
intuition. Yet hazard rates do not commonly increase–a brief
literature survey indicates that, with some exceptions, they are
usually flat or decreasing for the entire follow-up period. A more
thorough analysis of the models showed that the variability in
disease progression among patients tends to produce hazard rates
that decrease–and so this variability obscures interesting trends
that might otherwise be visible. In the future, as variability
decreases because patients are more accurately grouped according
to disease status (e.g. HER2 expression), we expect more
interesting trends in relapse data to appear. Even then, we would
forecast that from such data little can be gleaned about underlying
physio-pathological mechanisms. In summary, the models indicate
that one explanation for hazard rates which increase for many
years post-resection (the increase should continue for a time which
is longer than the time it takes for a micrometastasis to grow to a
clinically detectable size) is that micrometastases have increasing
tumourigenicities; non-increasing hazard rates do not imply that
there is no increase in tumourigenicity; no further information can
be deduced.
We draw the reader’s attention to one observation that is
potentially of clinical relevance: our models indicate that therapies
administered at around the time of surgery which either (a) induce
growth restriction among metastases or (b) reduce the number of
growth-restricted metastases, but which do not prevent cell
proliferation within metastases (and so prevent increases in their
tumourigenicity), may introduce a period during which patients
are prone to relapse. Again, this trend–a period during which
patients are prone to relapse–will only appear if the variability in
disease progression among patients of the cohort is sufficiently low.
New adjuvant anti-angiogenic therapies for various cancers
[37,38] that primarily block angiogenic proteins may cause
residual cancers to persist at a restricted size of approximately
1 mm in diameter, as has been seen in mouse models of
angiogenesis inhibition [8] (see review [37] and references therein).
Our study suggests that patients so treated should be monitored at
regular intervals for extended times.
This discussion relies on the validity of our key assumption, that
cancer dormancy is maintained by growth-restricted micrometas-
tases until a random event, occurring at a time that cannot be
precisely predicted, restarts growth to a clinically detectable
metastasis. The discussion is based on our analysis of four different
models of cancer dormancy. The models are distinguished by
different modes of disease progression during dormancy as is now
described. In Model 0, there is no disease progression, i.e. the risk
to each patient remains constant until a micrometastasis escapes
from growth restriction and so the patient no longer has
dormancy; in Model 1, disease progression occurs as micrometas-
tases are either newly seeded or eliminated; in Model 2, the chance
that micrometastases’ escape from growth restriction suddenly and
randomly increases owing, for example, to carcinogenic mutations;
while in Model 3, the chance that micrometastases’ escape from
growth restriction changes gradually and deterministically owing,
for example, to gradual changes in cell proliferation rates. Each of
Figure 2. Fitting models to relapse data. The Zeroth Model and Models 1–3 fitted to relapse data from two long-term follow-up studies: patients
are grouped by age in the study EBCTCG (Panel A), whereas patients are grouped by ER status in the study Chia et al. (Panel B). Black dots are data
points; solids curves are the models for the fitted parameters (Table 2). Hazard rates are inset.
doi:10.1371/journal.pone.0062320.g002
Table 2. Models fitted to relapse data.
Model Parameters Fitted parameters, Total squared deviation
EBCTCG, aged below 50 EBCTCG, aged 50–69
Zeroth {N,k} f0:55,0:12g, 2:3|10{5 f0:82,0:090g, 3:5|10{5
1 {N, k, m, l, pM} f4:1,0:016,0:10,0:19,0:017g, 2:5|10{5 f2:7,0:027,0:064,0:13,0:037g, 3:6|10{5
2 {Ns, NV, ks, kV} f1:2,0:32,0:015,0:22g, 2:1|10{5 f7:5,0:50,0:0026,0:15g, 2:3|10{5
3 fN,k0,k’0g f0:51,0:13,0:00041g, 3:5|10{5 f0:74,0:095,0:0026g, 5:0|10{5
Chia et al., ER+ Chia et al., ER2
Zeroth {N,k} f0:34,0:14g, 1:6|10{5 f0:22,0:29g, 2:7|10{5
1 {N, k, m, l, pM} f1:0,0:037,0:66,1:0,0:77g, 5:9|10{6 f1:2,0:053,0:24,0:024,0:023g, 2:8|10{5
2 {Ns, NV, ks, kV} f0:11,0:17,0:67,0:21g, 7:1|10{6 f0:001,0:22,0:0061,0:29g, 2:8|10{5
3 fN,k0,k’0g f0:24,0:15,0:046g, 5:8|10{6 f0:22,0:29,0:0024g, 2:8|10{5
Parameters fitted to EBCTCG relapse data and Chia et al. relapse data for the Zeroth Model and for Models 1–3. The growth time t is fixed at 3 years for EBCTCG data
and at 1:5 years for Chia et al. data.
doi:10.1371/journal.pone.0062320.t002
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the models, representing these different modes of disease
progression, support our conclusions above.
However, the models were designed to be very simple, and so
the inter- and intra-heterogeneity among the micrometastases of a
patient, owing to the genotypes or to the locations of microme-
tastases, were ignored. Further, how relapse rates are affected by
variability in the time it takes micrometastases to grow to a
detectable size was not investigated, because we opted to
concentrate on the dynamics of cancer dormancy which by
definition is before any micrometastases escape from growth
restriction. Nevertheless, we expect that even when this extra
variability is taken into account, then it would not alter the
conclusions above. (It is further work to determine how this extra
variability alters the estimates of the long-term averages and
Figure 3. Peaks in the relapse rate. RFI curves (top) and corresponding relapse rates (bottom) for Models 1–3 as parameters k (Model 1)/kV
(Model 2)/k0 (Model 3) are reduced. In each plot, k/kV /k0 decreases such that the ratio of the right-hand side to the left-hand side of the
corresponding inequality determining whether there is a peak in the relapse rate is 2 (long-dashed line), 1 (short-dashed line), 1/5 (dotted line) and 1/
25 (solid line).
doi:10.1371/journal.pone.0062320.g003
Figure 4. Estimates of means (top row) and standard deviations (bottom row) in patients’ numbers of micrometastases. This is up to
20 years post-resection for different values of k: k~0:20 (black), 0:05 (red), 0:02 (orange), 0:01 (green). The graphs use extrapolated hazard rates from
Models 0–3 (Figure 2) for the EBCTCG data set (panel A) and the Chia et al. data set (panel B). In each plot, graphs that have solid/dot-dashed/long-
dash/short-dash lines correspond to Zeroth Model/Model 1/Model 2/Model 3.
doi:10.1371/journal.pone.0062320.g004
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standard deviations in the number of patients’ micrometastases.
Inaccuracies in these estimates will also be produced by
inaccuracies in the relapse data–see the section` Relapse data’).
In order to improve our understanding of breast cancer
dormancy, it would be ideal to collect evidence that could be
used in conjunction with models like those presented in this article.
In the absence of methods for imaging and resecting microme-
tastases in patients, one possibility is to develop laboratory models,
probably mouse models, that permit micrometastases to be
observed over a long period and resected and genetically
sequenced at different stages of their progression. These laboratory
models might be used, for example, to validate our key
assumption, to establish whether micrometastases have increasing
tumourigenicity, and to improve estimates of the time it takes
micrometastases to grow to a detectable size. Genotyping and
quantitation of the circulating tumour cells in long-term post-
resection breast cancer patients (see e.g. [39]) might also provide a
means to determine the risk to a patient from cancer dormancy.
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